USPTO serial 98740258
TERNS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- PHILLIPS, WENDELL SHARMAN
- Law office
- TMO LAW OFFICE 110
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TERNS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tiffany D. Gehrke
Tiffany D. Gehrke Marshall, Gerstein & Borun LLP233 South Wacker Drive, Suite 6300Chicago, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, metabolic disorders, and endocrine disorders; Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; Peptides for pharmaceutical purposes, namely, for the treatment of cancer, metabolic disorders, and endocrine disorders. | ACTIVE | — |
| 042 | Pharmaceutical and biologic drug development services, namely, development of small-molecule drugs for use in humans; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; Research and development services in the field of pharmaceutical and biologic preparations; Research and development services in the field of oncology-related diseases and disorders; Research and development services in the field of metabolic-related diseases and disorders; Research and development services in the field of endocrine-related diseases and disorders; Research and development services in the fields of diabetes and obesity-related diseases and disorders; Research and development services in the field of peptide pharmaceutical preparations; Providing medical and scientific research information in the field of small-molecule drugs; Providing medical and scientific research information in the field of clinical trials and post-market trials; Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 25, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jul 24, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 24, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 24, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 24, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 24, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 24, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 11, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 9, 2024 | NWAP | NEW APPLICATION ENTERED | — |